To date, clinical data have been reported for two dual GIP/GLP-1 receptor agonists
Licensed options in the UK include orlistat (oral), semaglutide 2.4 mg (Wegovy, approved by NICE TA875 for eligible patients), and tirzepatide (Mounjaro for type 2 diabetes
The semaglutide and tirzepatide trials changed that expectation: Semaglutide 2.4 mg once weekly produced average weight loss around 15% at ~68 weeks in adults without diabetes, with a substantial fraction of participants losing 1520% of baseline weight
GLP-1 Therapies Outperform Bariatric Surgery in Cancer Risk Reduction A 2025 study published in eClinicalMedicine (Wolff Sagy Y et al.) compared cancer outcomes in patients receiving GLP-1 receptor agonists versus those who had undergone bariatric metabolic surgery
Researchers who sail through the week 24 period without concerning heart rate changes can generally be reassured that their cardiovascular response is within acceptable parameters for continued use
Drink plenty of water Regular fluid intake prevents dehydration, reducing the risk of constipation
